Results observed after Phenylbutazone and Enoxacin treatment were not significantly different from 0 Gy controls, suggesting they are protective (Fig
2) Gastrointestinal: Rarely, loss of appetite, nausea, vomiting, or stomach pain may occur
Metabolic indicators that may be associated with reduced GLP-1 activity include: Persistent elevated blood glucose levels , particularly postprandial (after-meal) hyperglycaemia Difficulty achieving or maintaining a healthy weight despite dietary efforts Increased appetite and reduced satiety after meals, leading to frequent snacking Diagnosis of type 2 diabetes or non-diabetic hyperglycaemia (NDH, sometimes called prediabetes), conditions where GLP-1 response is often blunted Features of metabolic syndrome , including central obesity, hypertension, and dyslipidaemia Individuals may also notice practical symptoms such as feeling hungry shortly after eating substantial meals, experiencing energy crashes following carbohydrate-rich foods, or finding portion control particularly challenging
Testosterone raised the risk of prostate cancer and exacerbated the effects of carcinogenic chemical exposure in rats
These habits nourish Akkermansia , boost short-chain fatty acids (SCFAs), and support natural GLP-1 rhythms
